Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
复制标题
基于提供者的研究网络和手术技术在早期肾癌患者中的传播。
DOI：
10.1002/cncr.29144
复制
发表时间：
2015
期刊：
影响因子：
6.2
通讯作者：
Nielsen,MatthewE
中科院分区：
文献类型：
--
作者：
Tan,Hung-Jui;Meyer,Anne-Marie;Kuo,Tzy-Mey;Smith,AngelaB;Wheeler,StephanieB;Carpenter,WilliamR;Nielsen,MatthewE
BACKGROUNDProvider‐based research networks such as the National Cancer Institute's Community Clinical Oncology Program (CCOP) have been shown to facilitate the translation of evidence‐based cancer care into clinical practice. This study compared the utilization of laparoscopy and partial nephrectomy among patients with early‐stage kidney cancer according to their exposure to CCOP‐affiliated providers.METHODSWith linked Surveillance, Epidemiology, and End Results–Medicare data, patients with T1aN0M0 kidney cancer who had been treated with nephrectomy from 2000 to 2007 were identified. For each patient, the receipt of care from a CCOP physician or hospital and treatment with laparoscopy or partial nephrectomy were determined. Adjusted for patient characteristics (eg, age, sex, and marital status) and other organizational features (eg, community hospital and National Cancer Institute–designated cancer center), multivariate logistic regression was used to estimate the association between each surgical innovation and CCOP affiliation.RESULTSDuring the study interval, 1578 patients (26.8%) were treated by a provider with a CCOP affiliation. Trends in the utilization of laparoscopy and partial nephrectomy remained similar between affiliated and nonaffiliated providers (P≥ .05). With adjustments for patient characteristics, organizational features, and clustering, no association was noted between CCOP affiliation and the use of laparoscopy (odds ratio [OR], 1.11; 95% confidence interval [CI], 0.81‐1.53) or partial nephrectomy (OR, 1.04; 95% CI, 0.82‐1.32) despite the more frequent receipt of these treatments in academic settings (P< .05).CONCLUSIONSAt a population level, patients treated by providers affiliated with CCOP were no more likely to receive at least 1 of 2 surgical innovations for treatment of their kidney cancer, indicating perhaps a more limited scope to provider‐based research networks as they pertain to translational efforts in cancer care.Cancer2015;121:836–843.©2014 American Cancer Society.
